[Federal Register Volume 70, Number 2 (Tuesday, January 4, 2005)]
[Notices]
[Page 392]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-63]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated July 8, 2004, and published in the Federal Register 
on July 20, 2004, (69 FR 43436), Johnson Matthey Inc., Custom 
Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 
08066, made application by letter to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
Dihydromorphine (9145), a basic class of controlled substance in 
Schedule I.
    The company plans to manufacture Dihydromorphine for internal use 
in production of other controlled substances for distribution to its 
customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Johnson Matthey Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Johnson Matthey Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-63 Filed 1-3-05; 8:45 am]
BILLING CODE 4410-09-P